Surgeries & Interventions

TAVR Long Term Outcomes Trump Surgery

A new JACC study highlighted the long term benefits of TAVR using the Evolut valve (Medtronic) compared to surgical AVR when it comes to avoiding bioprosthetic valve dysfunction (BVD).

  • Now over 20 years since the first TAVR, the method is an established alternative to surgery in patients with symptomatic severe AS, regardless of surgical risk.
  • However, while both TAVR and SAVR have their benefits in certain populations, few studies compare long-term valve stability between the two.

Pitting data from the two techniques head-to-head, researchers examined 5.6k patients from the US High Risk Pivotal and SURTAVI randomized controlled trials, finding that TAVR patients experienced significantly lower rates of BVD over the study’s five year follow-up.

  • Only 9.7% of patients undergoing TAVR with the Evolut valve experienced BVD, compared to 15.3% of surgical patients. 

Even though prosthetic valves can be replaced, valve dysfunction is still important to keep top of mind considering  the long-term survivability and quality-of-life impacts patients face following valve implantation.

  • In the case of this study, patients who experienced BVD faced a 49% greater all-cause mortality risk, 76% greater CV mortality risk, and 48% higher hospitalization rates.

Although TAVR’s benefits are pretty clear, there’s a catch – the study’s patient population consisted of mostly older patients (mean age 82), which could skew results away from surgery and toward TAVR.

  • The study’s data analysis also included 3,262 patients from non-randomized controlled trials, which is well over half (58%) of the study population.
  • Without built-in control and randomization, this patient data could also cast doubt on the impressive benefits seen.

The Takeaway

While it’s not a definitive slam dunk, the results of this data analysis study do support the trend that older AS patients certainly benefit more from non-invasive TAVR over the riskier surgical approach.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Heart Failure October 20, 2025

Don’t Blame Your Heart for Heart Failure October 20, 2025

Perhaps the biggest cardiology story of the year, an entire issue of JACC now hypothesizes that heart failure with preserved ejection fraction (HFpEF) might actually be caused by visceral fat tissue that triggers cardiac weakening through adipokine signaling. The new unifying adiposity framework now proposes that visceral fat expansion causes secretion of an altered adipokine […]

Cardiology Business October 16, 2025

MedAxiom Report: Cardiologist Compensation Soars, Patient Access Struggles October 16, 2025

Good news and bad news from MedAxiom’s latest cardiology compensation survey. The good news? Cardiologist median compensation reached new record highs last year. The bad news? Patient access deteriorated while the number of patients physicians had to manage swelled. The 2025 survey findings aggregated data across cardiology, cardiac surgery, and vascular surgery specialties, examining compensation […]

Heart Failure October 13, 2025

Specialist Care Can Improve HF Outcomes Across the Board October 13, 2025

A recent study out of the U.K. suggests that multidisciplinary team management could significantly reduce death or rehospitalization risk for HF patients across the LVEF spectrum. Based in a single U.K. county, the Buckinghamshire analysis examined 2.1k patients hospitalized for acute heart failure who received either specialist care or standard care over a 618-day follow-up […]